Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Cadranel

Showing results (271-280 of 329) with videos related to

Pageof 33
Sort By:
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Oncoimmunology|May 17, 2017
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapyHélène Roussel, Eléonore De Guillebon, Lucie Biard, et al.
Cancer Medicine|January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT StudyGeoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trialPierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
American Journal of Human Genetics|June 16, 2015
RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial SpokesLudovic Jeanson, Bruno Copin, Jean-François Papon, et al.
European Radiology|November 19, 2025
CT features of interstitial lung disease in systemic lupus erythematosus and overlap lupus-other connective tissue diseaseAurore Sajust de Bergues de Escalup, Arthur Mageau, Lou Deneuville, et al.
Annals of Translational Medicine|August 5, 2021
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assaySimon Heeke, Jonathan Benzaquen, Audrey Vallee, et al.
Nature Medicine|June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trialSolange Peters, Shirish M Gadgeel, Tony Mok, et al.
Pageof 33

Showing results (271-280 of 329) with videos related to

Sort By:
Pageof 33
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Oncoimmunology|May 17, 2017
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapyHélène Roussel, Eléonore De Guillebon, Lucie Biard, et al.
Cancer Medicine|January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT StudyGeoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trialPierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
American Journal of Human Genetics|June 16, 2015
RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial SpokesLudovic Jeanson, Bruno Copin, Jean-François Papon, et al.
European Radiology|November 19, 2025
CT features of interstitial lung disease in systemic lupus erythematosus and overlap lupus-other connective tissue diseaseAurore Sajust de Bergues de Escalup, Arthur Mageau, Lou Deneuville, et al.
Annals of Translational Medicine|August 5, 2021
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assaySimon Heeke, Jonathan Benzaquen, Audrey Vallee, et al.
Nature Medicine|June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trialSolange Peters, Shirish M Gadgeel, Tony Mok, et al.
Pageof 33